CorMedix Inc. (CRMD)

Market Cap	901.76M
Revenue (ttm)	121.48M
Net Income (ttm)	51.16M
Shares Out	74.65M
EPS (ttm)	0.79
PE Ratio	15.26
Forward PE	5.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,264,837
Open	11.84
Previous Close	11.50
Day's Range	11.63 - 12.50
52-Week Range	3.61 - 17.43
Beta	1.71
Analysts	Strong Buy
Price Target	16.83 (+39.32%)
Earnings Date	Aug 7, 2025

About CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Height...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2010
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: CRMD
• Website: https://www.cormedix.com

Analyst Forecast

According to 7 analysts, the average rating for CRMD stock is "Strong Buy." The 12-month stock price target is $16.83, which is an increase of 39.32% from the latest price.

Price Target

$16.83

(39.32% upside)

Analyst Consensus: Strong Buy